JCI Insight (Apr 2021)

Chronic HIV infection induces transcriptional and functional reprogramming of innate immune cells

  • Wouter A. van der Heijden,
  • Lisa Van de Wijer,
  • Farid Keramati,
  • Wim Trypsteen,
  • Sofie Rutsaert,
  • Rob ter Horst,
  • Martin Jaeger,
  • Hans J.P.M. Koenen,
  • Hendrik G. Stunnenberg,
  • Irma Joosten,
  • Paul E. Verweij,
  • Jan van Lunzen,
  • Charles A. Dinarello,
  • Leo A.B. Joosten,
  • Linos Vandekerckhove,
  • Mihai G. Netea,
  • André J.A.M. van der Ven,
  • Quirijn de Mast

Journal volume & issue
Vol. 6, no. 7

Abstract

Read online

Chronic inflammation and immune dysfunction play a key role in the development of non-AIDS–related comorbidities. The aim of our study was to characterize the functional phenotype of immune cells in people living with HIV (PLHIV). We enrolled a cross-sectional cohort study of PLHIV on stable antiretroviral therapy and healthy controls. We assessed ex vivo cytokine production capacity and transcriptomics of monocytes and T cells upon bacterial, fungal, and viral stimulation. PLHIV exhibited an exacerbated proinflammatory profile in monocyte-derived cytokines, but not in lymphocyte-derived cytokines. Particularly, the production of the IL-1β to imiquimod, E. coli LPS, and Mycobacterium tuberculosis was increased, and this production correlated with plasma concentrations of high-sensitivity C-reactive protein and soluble CD14. This increase in monocyte responsiveness remained stable over time in subsequent blood sampling after more than 1 year. Transcriptome analyses confirmed priming of the monocyte IL-1β pathway, consistent with a monocyte-trained immunity phenotype. Increased plasma concentrations of β-glucan, a well-known inducer of trained immunity, were associated with increased innate cytokine responses. Monocytes of PLHIV exhibited a sustained proinflammatory immune phenotype with priming of the IL-1β pathway. Training of the innate immune system in PLHIV likely plays a role in long-term HIV complications and provides a promising therapeutic target for inflammation-related comorbidities.

Keywords